A new grant has been awarded by the National Comprehensive Cancer Care Network® (NCCN) Oncology Research Program to a team comprised of PC3I Faculty, Advisors, and Affiliates to increase timely and equitable lung cancer screening (LCS) adherence across diverse populations. Katharine Rendle, PhD, MSW, MPH and Anil Vachani, MD, MSCE will serve as principal investigators alongside co-investigators Peter Gabriel, MD, MSCE; Rebecca Hubbard, PhD; Ravi Parikh, MD, MPP; and Richard Wender, MD.
Adherence to guideline-recommended annual LCS remains low, and disparities exist by race, sex, geography, and socioeconomic status. This grant will test patient and clinician nudge strategies to impact LCS adherence rates, including text messages to patients and electronic health record nudges to clinicians. Analyses will explore how patient, clinician, and system-level factors shape the effectiveness of nudge strategies, both overall and by subgroup. The research will benefit patients directly by identifying strategies to equitably increase LCS adherence.
Further information can be found in the press release by the National Comprehensive Care Network.
Despite known screening and diagnosis delays, PC3I finds the pandemic was not associated with treatment initiation delays or changes for patients with newly-diagnosed advanced cancer.
PC3I is pleased to share our 2020-2021 Impact Report, which shares highlights from our work over the past year to create, test, and scale solutions to some of the most intractable problems in cancer care delivery.
Dr. Charu Aggarwal will present on her work fully integrating plasma-based next-generation sequencing into clinical pathways to optimize detection of NCCN-recommended biomarkers in patients with newly diagnosed NSCLC.